Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup-Reference-Cited by-同舟云学术

Development of potent B-RafV600E inhibitors containing an arylsulfonamide headgroup

Published:2011-08 Issue:15 Volume:21 Page:4436-4440
ISSN:0960-894X
Container-title:Bioorganic & Medicinal Chemistry Letters
language:en
Short-container-title:Bioorganic & Medicinal Chemistry Letters

Author:

Stellwagen John C.,Adjabeng George M.,Arnone Marc R.,Dickerson Scott H.,Han Chao,Hornberger Keith R.,King Alastair J.,Mook Robert A.,Petrov Kimberly G.,Rheault Tara R.,Rominger Cynthia M.,Rossanese Olivia W.,Smitheman Kimberly N.,Waterson Alex G.,Uehling David E.

Publisher

Elsevier BV

Subject

Organic Chemistry,Clinical Biochemistry,Drug Discovery,Pharmaceutical Science,Molecular Biology,Molecular Medicine,Biochemistry

Reference10 articles.

1. Isotype-Specific Functions of Raf Kinases

2. Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF

3. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer

4. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. FDA-approved small molecule kinase inhibitors for cancer treatment (2001–2015): Medical indication, structural optimization, and binding mode Part I;Bioorganic & Medicinal Chemistry;2024-09

2. Identification of kinase modulators as host-directed therapeutics against intracellular methicillin-resistant Staphylococcus aureus;Frontiers in Cellular and Infection Microbiology;2024-03-25

3. BRAF/Multikinase Inhibitors;Molecules Engineered Against Oncogenic Proteins and Cancer;2023-09-08

4. Copper-Catalyzed Asymmetric Intermolecular N-Monoarylation of Unprotected Sulfonamides via Desymmetrization of Diaryliodonium Salts at Room Temperature;Synlett;2020-05-19

5. Improving the Dissolution Rate of the Anticancer Drug Dabrafenib;Crystal Growth & Design;2020-01-03